Summary of Significant Accounting Policies (Tables)

12 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Summary of Significant Customer Information

Significant customer information is as follows:

	March 31, 2023			March 31, 2022
Percentage of accounts receivable:
Customer C		69	%		25	%
Customer F		27	%		19	%
Customer G		0	%		44	%

	Year Ended March 31,
	2023			2022			2021
Percentage of revenue:
Customer C		22	%		20	%		21	%
Customer B		16	%		17	%		16	%

Schedule of estimated useful lives of property, plant and equipment

The estimated useful lives of the Company’s property and equipment are as follows:

Computer and software	3 years
Laboratory equipment and software	5 years
Furniture and office equipment	5 years
Leasehold improvements	Shorter of remaining lease term or estimated useful life

Summary of Revenue By Category

The following table presents revenue by category:

	Year Ended March 31,
	2023					2022					2021
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)
Point in Time
PGS	$	182,866		61	%	$	189,703		70	%	$	191,066		78	%
Telehealth		34,961		12	%		15,299		6	%		—		0	%
Consumer services		217,827		73	%		205,002		76	%		191,066		78	%
Research services		—		0	%		—		0	%		—		0	%
Therapeutics		—		0	%		—		0	%		54		0	%
Total	$	217,827		73	%	$	205,002		76	%	$	191,120		78	%
Over Time
PGS	$	19,548		7	%	$	12,978		5	%	$	6,459		3	%
Telehealth		9,761		3	%		3,908		1	%		—		0	%
Consumer services		29,309		10	%		16,886		6	%		6,459		3	%
Research services		52,353		17	%		50,005		18	%		46,341		19	%
Therapeutics		—		0	%		—		0	%		—		0	%
Total	$	81,662		27	%	$	66,891		24	%	$	52,800		22	%
Revenue by Category
PGS	$	202,414		68	%	$	202,681		75	%	$	197,525		81	%
Telehealth		44,722		15	%		19,207		7	%		—		0	%
Consumer services		247,136		83	%		221,888		82	%		197,525		81	%
Research services		52,353		17	%		50,005		18	%		46,341		19	%
Therapeutics		—		0	%		—		0	%		54		0	%
Total	$	299,489		100	%	$	271,893		100	%	$	243,920		100	%

Summary of Revenue by Region based on the Shipping Address of Customers

The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered:

	Year Ended March 31,
	2023					2022					2021
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)
United States	$	217,242		73	%	$	192,438		71	%	$	176,120		72	%
United Kingdom		63,023		21	%		58,477		22	%		49,386		20	%
Canada		13,581		4	%		14,293		5	%		12,172		5	%
Other regions		5,643		2	%		6,685		2	%		6,242		3	%
Total	$	299,489		100	%	$	271,893		100	%	$	243,920		100	%

Schedule Of Company Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:

	Year Ended March 31,
	2023			2022			2021
	(in thousands)
Segment Revenue:
Consumer and Research Services	$	299,489		$	271,893		$	243,866
Therapeutics		-			-			54
Total revenue	$	299,489		$	271,893		$	243,920
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(17,997	)	$	(30,112	)	$	12,796
Therapeutics Adjusted EBITDA		(88,503	)		(76,944	)		(58,734	)
Unallocated Corporate (1)		(54,801	)		(43,684	)		(30,587	)
Total Adjusted EBITDA	$	(161,301	)	$	(150,740	)	$	(76,525	)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(311,656	)	$	(217,490	)	$	(183,619	)
Adjustments
Interest income, net		(9,676	)		(277	)		(255	)
Other (income) expense, net		93			83			(1,322	)
Change in fair value of warrant liabilities		—			(32,989	)		—
Income tax benefit		(2,772	)		(3,480	)		—
Depreciation and amortization		20,239			18,899			20,246
Amortization of acquired intangible assets		16,486			7,269			—
Impairment of acquired intangible asset		9,968			—			—
Stock-based compensation expense		116,017			57,933			88,425
Acquisition-related costs (2)		—			9,362			—
Litigation settlement (3)		—			9,950			—
Total Adjusted EBITDA	$	(161,301	)	$	(150,740	)	$	(76,525	)

(1)Certain expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.

(2)For the fiscal year ended March 31, 2022, acquisition-related costs primarily consisted of advisory, legal and consulting fees.

(3)For the fiscal year ended March 31, 2022, litigation settlement is litigation cost net of insurance recoveries, which is not expected to occur on a recurring basis and not part of the Company's normal and continued business activity.

Summary of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:

	Year Ended March 31,
	2023				2022				2021
	(in thousands, except percentages)
Consumer and Research Services Segment Revenue:
Customer C (1)	$	65,721	22	%	$	53,875	20	%	$	51,786	21	%
Customer B (2)	$	47,448	16	%	$	46,064	17	%	$	39,917	16	%

(1)Customer C revenues are primarily in the United States.

(2)Customer B revenues are in the U.K.